Rosetta Genomics Granted US Patent for miRNA Used in Diagnostic Tests | GenomeWeb

Rosetta Genomics said this week that the US Patent and Trademark Office has issued US Patent No. 7,943,745, covering the composition of matter for human hsa-miR-497 and its variants.

The patent is not yet listed in the USPTO database.

Rosetta said that human hsa-miR-497 is an "important component" of its miRview Mets and miRview Mets2 diagnostic tests, used to identify the tissue of origin in cancers of unknown primary.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.